JPWO2020204172A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020204172A5
JPWO2020204172A5 JP2021512327A JP2021512327A JPWO2020204172A5 JP WO2020204172 A5 JPWO2020204172 A5 JP WO2020204172A5 JP 2021512327 A JP2021512327 A JP 2021512327A JP 2021512327 A JP2021512327 A JP 2021512327A JP WO2020204172 A5 JPWO2020204172 A5 JP WO2020204172A5
Authority
JP
Japan
Prior art keywords
methyl
alkyl
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021512327A
Other languages
English (en)
Japanese (ja)
Other versions
JP7539867B2 (ja
JPWO2020204172A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/015359 external-priority patent/WO2020204172A1/ja
Publication of JPWO2020204172A1 publication Critical patent/JPWO2020204172A1/ja
Publication of JPWO2020204172A5 publication Critical patent/JPWO2020204172A5/ja
Application granted granted Critical
Publication of JP7539867B2 publication Critical patent/JP7539867B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021512327A 2019-04-05 2020-04-03 水溶性アジュバント Active JP7539867B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019072910 2019-04-05
JP2019072910 2019-04-05
PCT/JP2020/015359 WO2020204172A1 (ja) 2019-04-05 2020-04-03 水溶性アジュバント

Publications (3)

Publication Number Publication Date
JPWO2020204172A1 JPWO2020204172A1 (https=) 2020-10-08
JPWO2020204172A5 true JPWO2020204172A5 (https=) 2023-04-12
JP7539867B2 JP7539867B2 (ja) 2024-08-26

Family

ID=72668226

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512327A Active JP7539867B2 (ja) 2019-04-05 2020-04-03 水溶性アジュバント

Country Status (8)

Country Link
US (1) US12427192B2 (https=)
EP (1) EP3949983A4 (https=)
JP (1) JP7539867B2 (https=)
KR (1) KR102921677B1 (https=)
CN (1) CN113966326A (https=)
CA (1) CA3136182A1 (https=)
MX (1) MX2021012201A (https=)
WO (1) WO2020204172A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024001843A (es) * 2021-08-12 2024-05-16 Int Inst Cancer Immunology Inc Composición farmacéutica y método para tratar o prevenir cáncer.
US20240115503A1 (en) * 2021-11-17 2024-04-11 Lipella Pharmaceuticals Inc. Intravesical delivery of hydrophilic therapeutic agents using liposomes
US12036318B2 (en) * 2022-02-16 2024-07-16 Chemical & Schutz High Performance Lubricants, S.A. De C.V. Self-emulsionable mineral oil as a vehicle in vaccines for poultry

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004268625B2 (en) * 2003-08-27 2011-03-31 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
EP1844789B8 (en) 2005-01-19 2014-10-08 Sumitomo Dainippon Pharma Co., Ltd. Emulsified composition for dilution and cancer vaccine composition
CA2631292C (en) 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Derivatised wt1 cancer antigen peptides and their use
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
SG11201507883SA (en) 2013-03-29 2015-10-29 Sumitomo Dainippon Pharma Co Ltd Wt1-antigen peptide conjugate vaccine
WO2017061532A1 (ja) * 2015-10-07 2017-04-13 大日本住友製薬株式会社 ピリミジン化合物
MX2018007319A (es) 2015-12-14 2018-09-06 Glaxosmithkline Biologicals Sa Imidazoquinolinas pegiladas como agonistas tlr7 y tlr8.
WO2018046460A1 (en) * 2016-09-07 2018-03-15 Glaxosmithkline Biologicals S.A. Imidazoquinoline derivatives and their use in therapy
KR102619747B1 (ko) * 2017-01-10 2023-12-29 넥타르 테라퓨틱스 Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법
EP3603619B1 (en) * 2017-03-29 2025-08-13 Sumitomo Pharma Co., Ltd. Vaccine adjuvant formulation

Similar Documents

Publication Publication Date Title
JPWO2020204172A5 (https=)
KR100268654B1 (ko) 아미노산 결합된 질소 머스타드 유도체 및 이를 종양 치료에 약물 전구체로서 사용하는 방법
US10005804B2 (en) TC-PTP inhibitors as APC activators for immunotherapy
US9642804B2 (en) Cationic lipids with various head groups for oligonucleotide delivery
JP7169968B2 (ja) ワクチンアジュバント製剤
Wu et al. Structure− activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides
JP2020533288A5 (https=)
PE20230834A1 (es) Antagonistas del receptor de lpa y usos de los mismos
JP2010528089A5 (https=)
JPH10508858A (ja) 改良抗ウイルス性プロドラッグ
ES2695302T3 (es) Novedosos inhibidores de DGAT2
EP2125007A2 (en) Conjugates of synthetic tlr agonists and uses therefor
JP7695789B2 (ja) ホスホ抗原プロドラッグ化合物
JP2024023349A5 (https=)
WO2009120999A2 (en) Use of an endoxifen prodrug for treatment of breast cancer
WO1991011994A1 (fr) Inhibiteur de la formation de lipoproteines denaturees de faible densite
EP3784662B1 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
CN1240451A (zh) 药用氨基膦酸衍生物
JP2016526023A (ja) Ｓｔａｔ６阻害剤
US20030220402A1 (en) Cancer remedy comprising anthranilic acid derivatives as active ingredients
JP2005527612A5 (https=)
RU2008111967A (ru) Липосомальные композиции
WO2011129837A1 (en) Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer
JPWO2020204173A5 (https=)
ES2236971T3 (es) Derivados del indol utiles, entre otras cosas, para el tratamiento de la osteoporosis.